In the award-winning project, Catalent brought extensive expertise in
softgel technology, over-encapsulation, and packaging to partner with a
leading pharmaceutical company to launch Duodart®, an innovative potent
fixed dose combination therapy medicine.
“We were especially pleased with this award, as it recognizes Catalent’s strength in bringing together a wide range of deep expertise and delivery technologies to solve complex developmental challenges for our customers. We value our close collaboration with our partner to help them bring this important new product to market,” said John Chiminski, Catalent’s President and Chief Executive Officer. “We are also delighted to once again win this prestigious award.”
This year Catalent was a finalist for the European Outsourcing Award in the Most Effective Scale-Up/Tech Transfer category for its involvement with the same product. Catalent was also a finalist in the Most Innovative Relationship category for its effective work on a new prenatal product formulation with a leading Japanese partner.
“We were especially pleased with this award, as it recognizes Catalent’s strength in bringing together a wide range of deep expertise and delivery technologies to solve complex developmental challenges for our customers. We value our close collaboration with our partner to help them bring this important new product to market,” said John Chiminski, Catalent’s President and Chief Executive Officer. “We are also delighted to once again win this prestigious award.”
This year Catalent was a finalist for the European Outsourcing Award in the Most Effective Scale-Up/Tech Transfer category for its involvement with the same product. Catalent was also a finalist in the Most Innovative Relationship category for its effective work on a new prenatal product formulation with a leading Japanese partner.
Companies in this press-release
